FIGURE 2.

Boxplot of the Post Hoc CL/F by Co‐administration of (A) CYP3A Inhibitors, (B) Posaconazole, (C) P‐gp Inhibitors, (D) AZA, DEC, and LDAC. Patients may appear in more than one category if co‐administration of CYP3A/P‐gp inhibitors changed during treatment. Patients on venetoclax plus AZA, DEC, or LDAC may also appear in venetoclax alone (Mono) if pharmacokinetic data were collected while on venetoclax alone. AZA, azacitidine; CYP3A, cytochrome P450 3A; DEC, decitabine; CL/F, apparent clearance; LDAC, low‐dose cytarabine